Find an Article

Filter articles

Applied Filters

Showing 81 to 90 of 142 results

SPCs: When a few days makes a difference

Austria, EU24-09-2015Anja Lunze and Paul England

An advocate-general at Europe’s highest court has said SPCs should come into effect once an applicant for a marketing authorisation has been notified of that authorisation. This is good news for SPC owners, say Anja Lunze and Paul England of Taylor Wessing.

London calling: the benefits of the UPC’s new home

UK10-09-2015Claire Phipps-Jones

Aldgate Tower will make an ideal home for the UK division of the UPC, with many advantages for its likely users, says Claire Phipps-Jones of Bristows.

From profits to damages: Canada’s NIA defence

Canada20-08-2015Mark Biernacki and Cameron Weir

A recent decision in Canada means defendants in patent infringement cases can raise the non-infringing alternative defence in response to damages claims. Mark Biernacki and Cameron Weir of Smart & Biggar/Fetherstonhaugh considers its potential impact on litigation between drugs companies.

Patent portfolios: maximise the value and minimise the cost

UK06-08-2015Bruno Reynolds

Proactively managing patent portfolios is an investment that pays for itself in reduced patent costs. Bruno Reynolds, who works at the consultancy arm of Isis Innovation, the technology transfer company of the University of Oxford, explains more.

Will you, won’t you, will you join the dance?

US30-07-2015Courtenay Brinckerhoff

On July 21 the US Court of Appeals for the Federal Circuit ruled in Amgen v Sandoz that biosimilar applicants can opt out of the ‘patent dance’. Courtenay Brinckerhoff of Foley & Lardner considers the decision’s implications for the biosimilars framework and highlights the questions that remain unanswered.

The devil in the judicial detail

International25-06-2015Paul England

The judiciary system for the new Unified Patent Court has been the subject of much discussion. As part of a regular column, Paul England, senior associate at law firm Taylor Wessing and who chaired a recent discussion between a panel of experts, examines the issue.

Stemming the tide of rejections

Mexico16-06-2015Jasmin Maqueda

Mexican patent examiners usually reject patents directed to human embryonic stem cells, but applications filed after 2008 may have a greater chance of being approved, as Jasmin Maqueda of Becerril, Coca & Becerril describes.

Gilead: Treating the seven million


Pharma company Gilead has been in the headlines since it launched its blockbuster drug Sovaldi with a hefty price tag. Less reported, however, are its numerous patent licensing deals that ensure wider access to medicines in the developing world. LSIPR spoke to Christina Carlson, senior counsel at Gilead Sciences, to find out more.

New players on the patent chess board

US14-05-2015Marc Cavan and Phillip Kurs

The ability of third parties to participate in patent challenges has led to new dynamics, including the possibility of parties profiting from movements in stock price and the prospect of patent oppositions by not-for-profit proxies, as Marc Cavan and Phillip Kurs of law firm Ropes & Gray describe.

UPC: keeping a weather eye

EU, US23-04-2015Paul England and Simon Cohen

In the second instalment of a regular column on the unitary patent and Unified Patent Court by law firm Taylor Wessing, Paul England and Simon Cohen discuss how watching the new system will also mean monitoring the old one.

Showing 81 to 90 of 142 results